You-Bo Peng

You-Bo Peng

Auto-generated profile, based on publicly available information

You-Bo Peng

Department of Nephrology, The First Affiliated Hospital of Kunming Medical University, Yunnan, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
YTYifang Tang
Yifang Tang
TLTao Liu
Tao Liu
SSShibo Sun
Shibo Sun
YPYoubo Peng
Youbo Peng
XHXiaoxiao Huang
Xiaoxiao Huang
ZZZhu Zhou
Zhu Zhou
GDF-15 is an essential member of the transforming growth factor-beta superfamily. Its functions mainly involve in tissue injury, inflammation, fibrosis, regulation of appetite and weight, development of tumor, and cardiovascular disease. GDF-15 is involved in various signaling pathways, such as MAPK pathway, PI3K/AKT pathway, STAT3 pathway, RET pathway, and SMAD pathway. In addition, several factors such as p53, ROS, and TNF-α participate the regulation of GDF-15. However, the specific mechanism of these factors regulating GDF-15 is still unclear and more research is needed to explore them. GDF-15 mainly improves the function of kidneys in CKD and plays an important role in the prediction of CKD progression and cardiovascular complications. In addition, the role of GDF-15 in the kidney may be related to the SMAD and MAPK pathways. However, the specific mechanism of these pathways remains unclear. Accordingly, more research on the specific mechanism of GDF-15 affecting kidney disease is needed in the future. In conclusion, GDF-15 may be a therapeutic target for kidney disease.

6 June 2025 in Journal of the Renin-Angiotensin-Aldosterone System
Verified
Journal Article
Closed access
WCWen-Kai Chu
Wen-Kai Chu
JHJie He
Jie He
YPYou-Bo Peng
You-Bo Peng
HFHong-Wei Fu
Hong-Wei Fu
VWVin-Cent Wu
Vin-Cent Wu
HYHong-Ling Yuan
Hong-Ling Yuan
Background: While the 1 mg dexamethasone suppression test (DST) is commonly used to diagnose mild autonomous cortisol secretion (MACS), the diagnostic utility of 24-h urinary free cortisol (24-h UFC) in patients with primary aldosteronism (PA) remains unclear. Methods: We prospectively enrolled 274 patients with confirmed PA between January 2017 and January 2020. MACS was defined by a post-DST serum cortisol level >1.8 μg/dL. Results: Among 274 PA patients (42.3% male; mean age, 55.9 ± 11.7 years)), 74 patients (27%) with PA had concomitant MACS while the other 200 patients were not. PA patients concomitant MACS were associated with higher 24-h UFC (OR, 1.91 [95% CI, 1.06–3.41], P = 0.03), older age (OR, 1.04 [95% CI, 1.01–1.07], P = 0.008), and diabetes mellitus (OR, 2.4 [95% CI, 1.12–5.12], P = 0.025). The 24-h UFC above 36 μg was associated with a positive predictive value of 32.6% and a negative predictive value of 77.9% for identifying concomitant MACS. Conclusions: Our study suggested the 24-h UFC less than 36 μg could help exclude MACS in PA cases. Combining this with 1 mg DST enhances accuracy. Additionally, older age and diabetes mellitus were also risk factors for predicting patients with PA concomitant MACS.